期刊文献+

高效液相色潽法测定马来酸阿法替尼对映异构体的含量 被引量:1

Determination of enantiomer of afatinib maleate by HPLC
下载PDF
导出
摘要 目的建立测定马来酸阿法替尼对映异构体的高效液相色谱方法。方法色谱柱为CHIRALPAK IC手性柱(250 mm×4.6 mm,5μm),以正己烷-二氯甲烷-无水乙醇-二乙胺(60∶40∶3∶0.1)为流动相,流速为0.8 m L·min-1,检测波长为250 nm,柱温为30℃,进样量10μL。结果马来酸阿法替尼及其对映异构体对照品浓度分别在0.429~5.150μg·m L-1(r=0.9997)及0.381~4.572μg·m L-1(r=0.9999)内线性关系良好;定量限浓度分别为0.286μg·m L-1、0.254μg·m L-1,检测限浓度分别为0.072μg·m L-1、0.064μg·m L-1,低、中、高3个浓度的供试品溶液平均回收率分别为99.6%、98.4%、97.6%,RSD分别为0.38%、2.4%、0.20%。结论本方法专属性强、准确度高,可用于马来酸阿法替尼对映异构体的质量控制。 ective To develop an HPLC method to determine the enantiomer of afatinib maleate. MethodsCHIRALPAK IC(250 mm×4.6 mm, 5 μm) was used with the mobile phase of n-hexane-dichloromethaneethanol-diethylamine(60∶40∶3∶0.1) at 0.8 m L·min- 1, and the detection wavelength was 250 nm. The column temperature was 30 ℃ and the injection volume was 10 μL. Results The method displayed a good linearity at 0.429- 5.150 μg·m L- 1(r = 0.9997) for afatinib maleate, and 0.381- 4.572 μg·m L- 1(r = 0.9999) for its enantiomer. The limit of quantification was 0.286 μg·m L- 1 and 0.254 μg·m L- 1, the limit of detection was 0.072 μg·m L- 1 and 0.064 μg·m L- 1, respectively. The average recovery was at 97.6%- 99.6%, with the RSD 3%. Conclusion The method is highly specific and accurate, which is suitable for the determination of enantiomer of afatinib maleate.
出处 《中南药学》 CAS 2016年第3期303-305,共3页 Central South Pharmacy
关键词 高效液相色谱法 马来酸阿法替尼 对映异构体 HPLC afatinib maleate enantiomer
  • 相关文献

参考文献6

二级参考文献167

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2Ferlay J, Shin HR, Bray F, et al. Parkin DM. Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12) :2893-917.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin,2007,57 ( 1 ) : 43-66.
  • 4Wang F,Wang S,Wang Z,et al. Phosphorylated EGFR expression may predicts outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR[J]. J Exp Clin Cancer Res, 2012,31 ( 1 ) : 65.
  • 5Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations (NEJ 003 study) [J]. J Thorac Oncol, 2012,7 (9):1417-22.
  • 6Oizumi S,Kobayashi K,Inoue A,et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of north east Japan study group 002 trial[J]. Oncologist, 2012,17 (6) : 863-70.
  • 7Kim ES, Hirsh V, Mok T, et al. Gefitinib versus doeetaxel in previously treated non-smalbeell lung cancer(INTEREST): arandomised phase Ⅲ trial [J]. Lancet, 2008, 372 (9652): 1809-18.
  • 8Fukuoka M,Wu YL,Thongprasert S,et al. Biomarker analyses and final overall survival results from a phase Ⅲ,randomized, open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients'with advanced non-small- cell lung cancer in Asia (IPASS) [ J ]. J Clin Oncol, 2011,29 (21): 2866-74.
  • 9Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patient with non small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11 (2) : 121-8.
  • 10Tony SK,Manolo D, Raffaele C. Clinical outcomes with Erlo tinib in patients with epidermal growth factor receptor mutation(NEJGSG002) [J]. Drugs,2012(72) :3-10.

共引文献54

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部